T2 Biosystems (TTOO) has provided an announcement.
The Company has shared significant business updates, including the anticipation of commercializing the T2Lyme Panel by the third quarter of 2024, which promises cost and efficiency benefits. A new study in the Journal of Clinical Microbiology has praised the T2Resistance Panel for its high accuracy and quick detection, which can improve clinical outcomes. Additionally, the Company is working with Dr. Robin Robinson, a seasoned biodefense expert, to market the T2Biothreat Panel. They’ve also been granted an extension by Nasdaq to meet the listing requirements by May 20, 2024.
Find detailed analytics on TTOO stock on TipRanks’ Stock Analysis page.
